Feb
2007
Enter your phone number (no dashes) and we'll call you now.
1-866-9-4EDGAR
Toll Free 24/7 (1-866-943-3427)
Fill out this form to get a free legal evaluation. A legal expert will examine your situation to see if you have a case.
Recent News
May
4
2012
Toning Shoes Can Cause Injuries
FDA Issues Warnings for ADHD Drugs
February 2007
If you, or someone you care about, take an Attention Deficit Hyperactivity Disorder (ADHD) medication, be aware of the potentially serious side effects. The Food and Drug Administration (FDA) has asked ADHD drug manufacturers to develop Patient Medication Guides outlining serious cardiovascular and psychiatric risks.
The ADHD medication in question includes the following products:
- Adderall
- Adderall XR
- Concerta
- Daytrana
- Desoxyn
- Dexedrine
- Focalin
- Focalin XR
- Metadate CD
- Methylin
- Methylin
- Ritalin
- Ritalin SR
- Ritalin LA
- Strattera
The adverse cardiovascular risks linked to ADHD drugs could lead to such complications as heart attack, stroke, and even sudden death. The adverse psychiatric risks could lead to such complications as hearing voices, mania, and paranoia. The risk of experiencing these symptoms may be increased by family history of similar complications. However, especially in the case of psychiatric effects, problems may surface with no previous medical history.
Have You Suffered Injuries Due to an ADHD Drug? Contact Us Now For a Free Evaluation of Your Legal Case.
Call us toll-free at 1-866-943-3427 or get online legal help, and we’ll give you a free evaluation of your claim.
Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Ohio and West Virginia, and we associate with experienced attorneys in other states. In addition, all drug-related litigation involves co-counsel.
Source: "FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events." FDA Press Release. February 21, 2007.
Source: "FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events." FDA Press Release. February 21, 2007.
